2023
Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014
Sankar A, Everhart A, Jena A, Jeffery M, Ross J, Shah N, Karaca-Mandic P. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. The Joint Commission Journal On Quality And Patient Safety 2023, 49: 458-466. PMID: 37380503, DOI: 10.1016/j.jcjq.2023.05.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseFDA safety communicationPhysician characteristicsLabel prescribingCare physiciansTestosterone prescribingService administrative claims dataNon-primary care physiciansCertain physician characteristicsDrug Administration (FDA) safety communicationPrimary care physiciansAdministrative claims dataCase mix indexTestosterone therapyArtery diseaseTestosterone prescriptionsPrescribing levelsMean agePrescription trendsTeaching hospitalClaims dataPrescription levelsMedicare feePrescribingUS Food
2021
U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016
Wallach JD, Rhee TG, Edelman EJ, Shah ND, O’Malley S, Ross JS. U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016. Journal Of General Internal Medicine 2021, 37: 495-498. PMID: 33674920, PMCID: PMC8811103, DOI: 10.1007/s11606-021-06668-x.Peer-Reviewed Original Research
2020
On-Label and Off-Label Clinical Studies of FDA–Approved Ophthalmic Therapeutics
Gopal AD, Wallach JD, Shah SA, Regillo C, Ross JS. On-Label and Off-Label Clinical Studies of FDA–Approved Ophthalmic Therapeutics. Ophthalmology 2020, 128: 332-334. PMID: 32682839, PMCID: PMC9900733, DOI: 10.1016/j.ophtha.2020.07.028.Peer-Reviewed Original Research
2018
Patterns and predictors of off-label prescription of psychiatric drugs
Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLOS ONE 2018, 13: e0198363. PMID: 30024873, PMCID: PMC6053129, DOI: 10.1371/journal.pone.0198363.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBipolar DisorderCitalopramCross-Sectional StudiesDrug PrescriptionsFemaleHumansInappropriate PrescribingInsurance, Major MedicalMaleMiddle AgedOff-Label UseOffice VisitsOutpatientsPractice Patterns, Physicians'Retrospective StudiesSleep Initiation and Maintenance DisordersTrazodoneUnited StatesConceptsNational Ambulatory Medical Care SurveyLabel prescribingChronic care managementPsychiatric drugsOutpatient visitsLabel prescriptionsCare managementAmbulatory Medical Care SurveyCommon off-label usesAdult outpatient visitsMore chronic conditionsMain outcome measuresOff-label useCross-sectional studyOff-label usesTypes of cliniciansManic-depressive psychosisStrong scientific evidenceVisit diagnosesAdverse eventsOffice visitsCare SurveyLabel usePsychiatric medicationsChronic conditionsOff-label Use of Medications—Reply
Wallach JD, Ross JS. Off-label Use of Medications—Reply. JAMA 2018, 320: 307-308. PMID: 30027247, DOI: 10.1001/jama.2018.6521.Commentaries, Editorials and LettersOff-Label UsePractice Patterns, Physicians'Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts
Wallach JD, Ross JS. Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts. JAMA 2018, 319: 776-778. PMID: 29486013, DOI: 10.1001/jama.2017.21897.Commentaries, Editorials and LettersDirect-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines
Klara K, Kim J, Ross JS. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. Journal Of General Internal Medicine 2018, 33: 651-658. PMID: 29484575, PMCID: PMC5910340, DOI: 10.1007/s11606-017-4274-9.Peer-Reviewed Original ResearchConceptsDTC adsDiabetes medicationsPresentation of risksLabel promotionPrescription drugsBlood pressure reductionFDA guidelinesBladder dysfunctionDiabetic neuropathyResultsOur sampleChronic conditionsInflammatory conditionsAllergic reactionsLabel usesPrescribers' decisionsUnique drugDrug AdministrationDrug risksDrug efficacyPressure reductionOff-label promotionWeight lossAdvertisement claimsConsumer advertisementsDrugs